Clinical Trial Update: rhPTH Therapy for Low Turnover Bone Fragility [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on recombinant human parathyroid hormone therapy for low turnover bone fragility in osteopetrosis; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopetrosis

Drugs mentioned

• rhPTH Therapy (recombinant human parathyroid hormone)

Snippet

Sponsor: University of Chicago | Conditions: Osteopetrosis | Phase 1 | Status: TERMINATED